7 withdrawn. 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Withdrawn 7 |
Follow Complementary Therapies: new trials by email Literature Review of Complementary Therapies trials Research Report on Complementary Therapies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer antineoplaston A10, antineoplaston AS2-1, bicalutamide - Adenocarcinoma of the Prostate, Stage III Prostate Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| Antineoplaston Therapy in Treating Women With Advanced Breast Cancer antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Stage IV Breast Cancer, Recurrent Breast Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| Antineoplaston Therapy in Treating Patients With Mantle Cell Lymphoma antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| Antineoplaston Therapy in Treating Patients With Colon Cancer antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Stage IV Colon Cancer, Recurrent Colon Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Merkel Cell Carcinoma, Islet Cell Carcinoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| Methotrexate With or Without Antineoplaston Therapy in Treating Postmenopausal Women With Advanced Refractory Breast Cancer antineoplaston A10, methotrexate, alternative product therapy - Stage IV Breast Cancer, Recurrent Breast Cancer | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 | ||
| Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma antineoplaston A10, antineoplaston AS2-1, alternative product therapy - Primary Central Nervous System Lymphoma | Phase 2 | Withdrawn | Burzynski Research Institute | 2013-07-10 |
Breast Neoplasms (2) · Carcinoma, Islet Cell (1) · Carcinoma, Merkel Cell (1) · Carcinoma, Neuroendocrine (1) · Colonic Neoplasms (1) · Growth Hormone-Secreting Pituitary Adenoma (1) · Lymphoma, Mantle-Cell (1) · Pituitary Neoplasms (1) · Prostatic Neoplasms (1) · Somatostatinoma (1)
Burzynski Research Institute (7)
United States (7)